GlassScriptPhysician profile
Irinel Stanciu
NPI 1720068760
$103,948.23
in general payments reported to CMS, 2019-2025
19 companies · $12K in 2025
The $12K reported for 2025 was more than what 91% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,151 · 2020: $17K · 2021: $9,778 · 2022: $9,905 · 2023: $40K · 2024: $8,207 · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $46K · Travel and Lodging: $7,470 · Food and Beverage: $4,043 · Consulting Fee: $2,880 · Education: $9.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $46,334.00 |
| Travel and Lodging | $7,469.93 |
| Food and Beverage | $4,042.91 |
| Consulting Fee | $2,880.00 |
| Education | $9.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $65,208.02 | 2019-2025 | Strensiq |
| Radius Health, INC. | $20,633.91 | 2019-2025 | Tymlos |
| Amgen INC. | $11,465.43 | 2019-2025 | Evenity, Prolia |
| Ultragenyx Pharmaceutical INC. | $3,886.18 | 2019-2023 | |
| Ascendis Pharma Endocrinology INC | $1,096.73 | 2023-2025 | Yorvipath |
| Kyowa Kirin, INC. | $491.20 | 2023-2025 | Crysvita |
| Lilly USA, LLC | $333.38 | 2022-2024 | Mounjaro, Jardiance, Zepbound |
| Ucb, INC. | $189.16 | 2021 | |
| Shire North American Group INC | $136.56 | 2019 | |
| Novo Nordisk INC | $120.89 | 2025 | Ozempic |
| Corcept Therapeutics | $110.40 | 2022-2023 | Korlym |
| Dexcom, INC. | $86.67 | 2024-2025 | Dexcom G6 Transmitter |
| Tandem Diabetes Care, INC. | $73.53 | 2024-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Abbott Laboratories | $49.29 | 2024-2025 | Freestyle Libre 3 |
| Beta Bionics, INC. | $18.67 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ascensia Diabetes Care US INC. | $17.05 | 2024 | |
| Sequel Med Tech, LLC | $16.31 | 2025 | Twiist |
| Medtronic, INC. | $14.85 | 2025 | Minimed 780g |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Irinel Stanciu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.